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 Abstract 
  
Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality 
following heart attacks in patients who develop indications of congestive heart failure. In the 
paediatric population it is used most commonly for the treatment of heart failure, 
hypertension in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid 
formulation, the current study evaluates the development of a range of oral liquid 
formulations of ramipril along with their in vitro and in vivo absorption studies. Three different 
formulation development approaches were studied: solubilisation using acetic acid as a co-
solvent, complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and suspension 
development using xanthan gum. Systematic optimisation of formulation parameters for the 
different strategies resulted in the development of products stable for twelve months at long 
term stability conditions. In vivo evaluation showed CMAX of 10.48 µg/mL for co-solvent, 
13.04µg/ml for the suspension and 29.58µg/mL for the cyclodextrin based ramipril solution. 
Interestingly, both ramipril solution (co-solvent) and the suspension showed a TMAX of 2.5h, 
however, cyclodextrin based ramipril produced TMAX at 0.75h following administration.  The 
results presented in this study provide translatable products for oral liquid ramipril which offer 
preferential paediatric use over existing alternatives. 
 
 
 
 
 
 
 Introduction 
 Ramipril is used mainly in the treatment of mild to severe hypertension as well as to 
reduce the incidence of fatality following heart attacks in patients who develop indications of 
congestive heart failure. It may also be used to slow the progression of kidney disease in 
patients who suffer from high blood pressure in conditions such as diabetes,(1–3) 
microalbuminuria (albumin in the urine) or nephropathy. (2,3) Once administered, maximum 
absorption is approximately 50-60%(4) through solute transporters in the small intestine.(5) 
In the paediatric population, ramipril is used most commonly for the treatment of heart failure, 
hypertension in children with type 1 diabetes and also in the treatment of diabetic 
nephropathy.(6) 
 Solid oral dosage forms are the preferred method of administration for the general 
population. These however are often difficult or impossible for paediatric patients to swallow 
safely. (7) The preferred dosage forms for children include oral solutions, syrups, 
suspensions, and drops due to their wider acceptability and dose flexibility. Additionally, 
liquid forms of medication may also be administered by oral feeding tube when required. (8) 
Dose volume is a critical factor to consider during formulation development as the typical 
target dose volumes for paediatric liquid formulations are ≤5ml for children younger than 5 
years and ≤10ml for children 5 years and older.  
 During formulation, the physiochemical properties of the drug governs the route of 
formulation with solubility, pKa, and palatability being primary concerns. Careful excipient 
selection is imperative when targeting paediatrics to achieve the desired formulation effect 
whilst still accommodating the highly sensitive nature of the patient segment. The European 
Medicines Agency (EMEA) acknowledges that there may be no single formulation which 
meets all requirements for all paediatric age groups but dosage forms containing minimal 
number and quantities of excipients which offer dose flexibility and cheaper cost of 
production are preferred (EMEA/CHMP/PEG/194810/2005).(9)       
 Ramipril is commercially available as tablets, capsules and oral solution. However, 
the oral liquid is not prescribed for paediatric population owing to the reported toxicity 
implications associated with the use of high concentration of propylene glycol (E1520) within 
the formulation (EMEA/CHMP/PEG/194810/2005). (11) Research into the production of an 
age appropriate dosage form targeting paediatrics, was considered a priority as 
communicated in the revised priority list for studies into off-patent paediatric medicinal 
products (EMA/480197/2010).(10)  
 The current study aims to develop oral liquid formulations of ramipril which offers 
target pharmaceutical product profile (TPPP) comprising of small dose volume (not more 
than 5 mL to deliver 5mg, which is the common dose in children), long term stability, reduced 
dosing frequency (related to dose volume), flexibility for dose manipulation and evidence of 
biopharmaceutical performance. Three different strategies which included two solution 
based and one suspension based formulation approaches that meet the TPPP were 
investigated. Solubilisation of ramipril was studied using  acetic acid as a co-solvent and 
through complexation  with hydroxypropyl-β-cyclodextrin (HP-β-CD) whereas suspension 
was formulated using hydrophilic suspending agent. 
 Acetic acid was selected for use as a co-solvent in the solubilisation of ramipril as it 
dissolves the drug freely and is Generally Recognised as Safe (GRAS).  Similarly, HP-β-CD 
(modified β-CD) was used for drug complexation as it offers improved solubility when 
compared to the parent molecule which would result in a linear relationship between the 
improvement in apparent solubility (drug) with increasing cyclodextrin concentration. 
Although parenteral administration of beta cyclodextrins may lead to nephrotoxicity, oral 
delivery is considered safe due to their low bioavailability (<1%).(12)  
 The formulation of oral suspension of ramipril was studied using xanthan gum as the 
suspending agent due to its pseudoplastic properties and solubility in water. Additionally, 
xanthan gum is suitable for use in a wide range of pH (between 3-12) which has benefits 
over hydrophobic polymers such as ethylcellulose which are sensitive to acidic conditions 
(as ramipril is most stable in an acidic environment) and require heating and cooling cycles 
to achieve solubilisation.  
 Following formulation development, stability testing was carried out to ensure that the 
formulations achieved the long term stability requirement listed in the TPPP. 
Biopharmaceutical performance of the dosage forms was evaluated and included the 
measurement of drug permeability using cell culture models followed by in vivo assessment 
in rats to determine the pharmacokinetic profile. Previous work has reported a correlation of 
R2=0.88 for drug absorption between humans and rats. (13) Similarly, drug absorption 
studies in the small intestine of humans and rats showed a linear correlation (R2=0.8) for 
both passive and carrier mediated absorption pathways. (14)  
 
Materials  
 Ramipril was purchased from Discovery Fine Chemicals (UK). Solvents for HPLC 
were supplied by Fisher Scientific (UK). Xantural® was purchased from Azelis (UK). All other 
reagents including HP-β-CD, NaOH, HCl, Tween 20, 40, 60 and 80, Span 20, 40, 60 and 80 
and tissue culture media items were obtained from Sigma (UK) Ltd. Gibco Invitrogen (UK) 
supplied Hanks Balanced Salt Solution (HBSS) for tissue culture use.  
Methods 
HPLC method for the detection of ramipril 
 A Dionex GP50 Gradient Pump coupled to a Dionex UVD170U detector and a 
Dionex A550 auto sampler was used for HPLC studies. Perchlorate Buffer and Acetonitrile 
(55:45) was used as the mobile phase and the stationary phase was a C18 reverse phase 
column (150 x 4.5mm with 5µm Particle Size) with a flow rate of 1mL/min at a detection 
wavelength of 216nm. The injection volume was 50µl and the run time was 10 minutes (min). 
Calibration standards were produced via serial dilution in methanol and acetonitrile (Diluent 
A) (50:50). The standards were then diluted 1:5 in diluent B (water and acetonitrile, 45:55). 
The method was validated following the guidelines from International Conference on 
Harmonisation (ICH) (ICH Topic Q 2 (R1) 1995).(15) 
Method for particle size analysis 
 Particle size for suspensions was measured using Sympatec Helos (UK) particle 
sizer. For the measurements of size, 100 μL of a sample was pipetted into a glass quartz 
cuvette (a signal of at least 15% scattering was required for an adequate reading). Three 
measurements were taken for each formulation and an average result obtained for size and 
polydispersity.  
Method for zeta potential analysis 
 Zeta potential was analysed using a Brookhaven zeta potential analyser in 
conjunction with a BI-ZEL electrode assembly (Brookhaven Instruments). A 1:10 dilution was 
made of each formulation in distilled water to bring detection levels into a readable range 
and placed into the zetasizer cuvette. Triplicate readings were taken from three batches for 
each formulation and the mean value reported. 
Co-solvent approach to the solubilisation of ramipril 
 Acetic acid solutions were produced at concentrations of 4%, 3%, 2%, 1%, 0.5%, 
0.1%, 0.05%, 0.04%, 0.03%, 0.02% and 0.01% v/v. Ramipril was then added to each co 
solvent at 0.01%w/v. The solutions were stirred for 1 hour (h) and filtered before HPLC to 
confirm complete solubilisation.  
 
 Cyclodextrin Approach to the Solubilisation of Ramipril 
Phase solubility 
 Method described by Higuchi and Connors was used to investigate phase solubility of 
ramipril and HP-β-CD complex.(16) This method was also adapted to assay the effect of 
temperature and pH on solubilisation. Six concentrations of cyclodextrin were produced in 
distilled water ranging between 1.2mM to 3.75µM using serial dilution. These were cooled to 
15°C and excess ramipril was added. Solutions were then maintained at this temperature for 
1h at which point a sample was taken, filtered and prepared for HPLC. This was repeated at 
30°C, 45°C, 60°C and 75°C. Similarly for pH, six concentrations of cyclodextrin were 
produced  from 1.2mM down to 3.75µM using serial dilution. These were produced at pH 3, 
5 and 7 to which excess ramipril was added. Solutions were left stirring for 1h before 
samples were filtered and prepared for HPLC analysis. 
Determination of ramipril – HP-β-CD binding constant and stoichiometry 
 In order to identify the binding constant and stoichiometry for drug-cyclodextrin 
complex, known amounts of ramipril were added to 4.8x10-3M solution of HP-β-CD in water 
at increasing increments of 1.0x10-3M up to 1.0x10-2M. Temperature was maintained at 25°C 
and pH was recorded throughout. Conductometry readings were taken using a 
conductometer equipped with a probe containing 2 platinum electrodes (surface 1 cm2, 
separation distance of 1 cm) after each addition of drug. A graph of the conductance 
readings was produced. Stoichiometry and binding constant of the drug-cyclodextrin 
complex was calculated by plotting conductance against the molar ratio of cyclodextrin.  
Suspension approach to ramipril Fformulation 
Rheology  
 Ramipril suspensions containing 0.1-0.5%w/v (recommended concentration as 
suspending agent) of  Xantural® were prepared to study flow behaviour. Suspension 
rheology was investigated to provide information on flow properties by measuring 
suspension viscosity at different shear rates using a Brookfield DV – I + Viscometer at shear 
rates of 0.08, 0.16, 0.32, 0.83 and 1.67 reciprocal seconds  at 20°C. 
Investigation into the rate and volume of sedimentation 
 The theoretical rate and volume of sedimentation was calculated using Stokes 
equation. For investigation into the actual rate and volume of sedimentation, ramipril 
suspensions containing 0.1-0.5%w/v Xantural® were prepared and allowed to stand 
undisturbed for four weeks at 20°C. Actual sedimentation was obtained from the 
sedimentation volume. Studies were carried out on three different batches of the 
formulations. 
 
Particle size and investigation into Ostwald Ripening 
 Ramipril suspensions were produced in distilled water using Xantural® 180 at 
concentrations ranging between 0.1-0.5% w/v and particle size was measured using a 
Sympatec HELIOS/BF particle size analyser. The suspensions were heated and cooled 
repeatedly and particle size was measured after each cycle. Microscopic images were also 
recorded to document any crystal growth. Each cycle involved heating to 40°C for 24h  
followed by cooling to 4°C for 24h . Studies were carried out on three different batches of the 
formulations. 
Analysis of zeta potential 
 Ramipril suspensions (0.1-0.5%w/v Xantural® 180) were analysed using a zeta plus 
zeta potential analyser in conjunction with a BI-ZEL electrode assembly (Brookhaven 
Instruments). 100µl of the formulation was added to the cuvette containing approximately 
1.5ml of distilled water and zeta potential was recorded on three different batches of the 
same formulation. The values presented are the mean of the three measurements. 
Stability analysis 
 The conditions for stability testing were based on the guidelines set out in the ICH 
Harmonisation Guidelines Q1A(R2).(17) Stability investigations were carried out at 40°C and 
75% humidity for accelerated testing and 25°C and 60% humidity for long term stability 
testing. The final formulations were tested on a monthly basis and assessed quantitatively by 
HPLC and for pH. Formulations were also assessed qualitatively for colour changes and 
odour and suspensions were assessed for resuspendibility of any sediment. 
Assessment of absorption In Vitro 
Culture of Caco-2 cells for permeability assay  
 Caco-2 cells (passage 45) (A kind gift from Dr Andrew Collett and Dr Daniel Patten at 
the University of Huddersfield) were seeded at a density of 1.3x105 cells/cm2 onto 
permeability supports (Appelton Woods Ltd). Cells were cultured in an incubator (Sanyo) at 
37°C in a humidified 5% CO2/95% air atmosphere. Media was changed every 2-3 days over 
a three week period. Trans-epithelial electronic resistance (TEER) measurements were 
taken following each media change and immediately before and after experiments using an 
EVOM – Epithelial Voltohmmeter (World Precision Instruments Ltd). Minimum TEER 
threshold of 350Ωcm2 (before and after the experiment) was set as a standard to ensure 
monolayer integrity.  
Trans-epithelial flux of ramipril across Caco-2 monolayers 
 Culture media was removed and the monolayers were washed and incubated (pH 
range 6.7 - 7.8)  at 37°C for 30min with 2.5ml and 1.5ml of HBSS basolaterally and apically 
respectively. In each case, HBSS was then replaced in the apical compartment with 1.5ml of 
the optimised formulation to be tested. Monolayer containing transwells (not exposed to the 
drug) were used as controls.  200µl samples were then taken from the basolateral 
compartment at time points of 5, 10, 15, 20, 30, 60, 90, and 120min. 200µl of HBSS was 
added in each case to maintain volume of solution in the basolateral compartment which 
was accounted for in calculations. Samples were analysed via HPLC. All of the experiments 
were performed in triplicate and the level of transport was described as the percentage of 
drug arriving in the basolateral compartment. Following the production of a transport/time 
graph which displays the rate of drug transport form the apical to basolateral chamber of the 
permeability support over the time of the assay, Papp was calculated.(18) 
Genomic profiling of Caco-2 following in vitro absorption studies 
 Investigation into gene expression changes of Caco-2 cells following drug transport 
studies were intended to identify link between the predicted drug permeability and the 
expression of the genes which code for the intestinal transporters of ramipril. Microarray 
assay was performed on RNA samples collected from Caco-2 cells following trans-epithelial 
flux experiments on ramipril solutions developed using co-solvency and cyclodextrin 
approaches in addition to the suspension formulation.  These assays were carried out 
following the directions for Agilent Technologies’ one-colour microarray-based gene 
expression analysis low input quick amp labelling kit. In short, 1.5µl of 50ng total RNA was 
mixed with 2µl of spike mix (dilution 4), cDNA master mix (Agilent Technologies, Santa Clara, 
CA) was used to prepare cDNA for all samples ahead of labelling with cyanine 3-CTP (Cy3) 
in the labelling reaction. The labelled and amplified cRNA was then purified using RNeasy 
mini spin columns (Qiagen) and quantified using Nanodrop ND-1000 UV-VIS 
spectrophotometer (Thermoscientific, Wilmington, DE). All samples were then hybridised to 
Agilent 4x44K whole genome arrays for 17(h) at 65°C in a hybridisation oven (Sheldon 
manufacturer, Corneilus, OR). Following the hybridisation stage slides were washed using 
the gene expression wash buffer kit (Agilent Technologies, Santa Clara, CA) and acetonitrile. 
Scanning was carried out at using Agilent Scanner (Agilent Technologies, Santa Clara, CA) 
at a resolution of 50n. Feature Extraction software (V10.7, Santa Clara, CA) was 
implemented to examine the quality of the 16-bit TIFF images obtained by microarray 
scanning.  
 Statistical analysis was carried out using Significance Analysis of Microarrays (SAM) 
to identify statistically significant genes which demonstrated either a 2 fold up regulation in 
expression or a 2 fold down regulation in gene expression when compared to their 
expression levels in control populations. Delta values were selected so as that the median 
false discovery rate (FDR) was lower than 5%. These gene lists were then exported to 
EXCEL where the gene tables of SLC and ABC genes were prepared for data entry into the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) http://www.genome.jp/kegg/. (19) 
Assessment of absorption in vivo. 
 Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK) and was 
carried out in a designated establishment. Wistar rats with a body weight of approximately 
250g-300g were used. Prepared formulations were loaded into a 1ml syringe and 
administered via oral gavage. Dosing was calculated depending upon the weight of each 
individual animal (5mg/kg) and formulations were diluted in water. Following dosing, an 
additional 1ml of H2O was administered to rinse in the formulations. Blood samples (45µl) 
were taken via tail bleeds at 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h and 4h time points 
following administration. Plasma was extracted from blood samples by centrifugation at 2800 
x g for 10min. The plasma samples were then diluted 1:5 in mobile phase and analysed 
using HPLC. 
  
 
 
 
 
  
 
Results and Discussion 
 The first phase of product development was focused on excipient selection and 
process optimisation. One of the main considerations was to ensure that the formulations 
were developed with  minimal number of excipients at their lowest possible concentration.  
The first approach towards the development of oral liquid solution was studied using acetic 
acid as a co-solvent to enhance the apparent solubility of ramipril.  
Co-solvent approach to the solubilisation of ramipril 
 Initial investigations were focussed on solubility profiling of ramipril following the 
addition of a range of different concentrations of acetic acid in water. Acetic acid-water co 
solvents were prepared in the concentration range between 0.01 – 4%v/v of acetic acid and 
the solubility of ramipril was assessed using HPLC. The various co solvent mixtures were 
also assessed for their organoleptic properties such as colour and smell as well as their final 
pH. All of the co-solvent solutions achieved complete solubilisation of ramipril to form 
colourless solutions. The pH of the solutions became less acidic as the acetic acid 
concentration decreased. For instance, the pH of the lowest acetic acid concentration 
(0.01%v/v) was 3.8 and the highest acetic acid concentration (4.0%v/v) was 2.4. For all of 
the solutions, the smell of  acetic acid was negligible.  
  Ramipril was solubilised utilising acetic acid and distilled water as a co-solvent 
system even at acetic acid concentrations as low as 0.01% (v/v). This lends itself to use in 
the production of an oral liquid dosage form as the low levels of co-solvent are ideal. This is 
of particular importance when targeting paediatrics and especially so with acetic acid owing 
to unpleasant taste and smell being potentially significant factors. Additionally, low 
concentrations of acetic acid minimises requirements for taste and odour masking.  The 
concentration of acetic acid solution deemed most suitable for use in the solubilisation of 
ramipril was 0.02% (v/v). This was the lowest concentration at which  instantaneous 
solubilisation was achieved at the same time  yielding a suitable pH (3.7), colour (clear) and 
odour (odourless).  
The final formulation composition and process consisted of addition of 1mg/ml of ramipril into 
0.02% v/v acetic acid - water cosolvent  mixture under stirring to ensure complete 
solubilisation and homogeneity. This was followed by the addition of other excipients in the 
following order: ascorbic (0.1mg/ml; antioxidant), xylitol (200mg/ml; sweetener), parabens 
(propyl -0.1mg/ml, butyl – 0.06mg/ml; preservative) and finally orange flavour (0.1%v/v) 
(Table 1).    
Cyclodextrin approach to solubilising ramipril 
Cyclodextrin based liquid dosage forms were investigated as they provide dual advantage 
including enhancement of apparent drug solubility as well as taste masking through drug 
encapsulation.  
Phase Solubility  
 Phase solubility profile of ramipril in the presence of various concentrations HP-β-CD 
was studied to identify the stoichiometry during drug-complex formation. The results showed 
that the phase solubility profile for ramipril complexed with HP-β-CD was that of the AL type 
(Figure 1) which demonstrates a linear relationship between the increase in drug 
solubilisation  with the increase in cyclodextrin concentration. This is particularly useful as 
the linear relationship allows for close estimation of the concentration of cyclodextrin needed 
to solubilise a chosen concentration of ramipril.  Using the gradient from the equation for the 
line it can be estimated that there was a 1:1 molar  binding ratio between ramipril and 
cyclodextrin molecules. In the current study, as the target dose of  ramipril in the formulation 
is 1mg/ml (which equates to 0.24mM), it can be estimated that 0.24mM of cyclodextrin will 
be required to solubilise the drug (0.24mM equates to 3.5mg/ml).  
 Drug solubility following complexation with cyclodextrin has been show to vary upon 
modification of the pH of a system. This possibly occurs as a result of alteration to the 
complexation constant with solubility increases resulting in an increase in complexation 
constant.(20) As shown  in Figure 2, the optimum pH for the solubilisation of ramipril using 
HP-β-CD was  3 with both pH 5 and 7 showing reduced solubilisation. These differences in 
solubilisation at different pH values could possibly be due to the existence of either ionised 
or un ionised form of the drug.  The concentration of ionised form of ramipril is higher at pH 
close to neutral and previous research has shown that the degree of complex formation for  
HP-β-CD is lowered for  ionised molecules when compared with their uncharged form.(21) 
The negative charge present following ionisation of ramipril could result in repulsive forces 
between cyclodextrin and drug molecules and between drug molecules leading to a 
reduction in complexation. 
Following the evaluation of drug-cyclodextrin molar ratio and the impact of pH on the 
resultant complex, the production of the formulation consisted of the preparation of 
cyclodextrin solution by dissolving 3.51mg/mL of HP-β-CD in distilled water. The next stage 
included the addition of 1mg/ml ramipril under stirring until it was completely dissolved. 
Following this, the other excipients were added in the following order: ascorbic (0.1mg/ml; 
antioxidant), xylitol (200mg/ml; sweetener), parabens (propyl - 0.1mg/ml, butyl – 0.06mg/ml; 
preservative) and finally orange flavour (0.1%v/v) (Table 1). The pH of the final formulation 
was pH 3.75. 
 
 
 
 
 Suspension formulation development 
The development of a suspension requires selection and optimisation of a suitable 
concentration of suspending agent along with the assessment of sedimentation rate and re- 
suspendibility of the formulation. 
Suspension Rheology, rate and volume of sedimentation 
 The first sets of investigations included determination of flow properties of the 
suspending medium using shear rate response to changes in shear stress which was 
evaluated using a viscometer. Five different suspensions were produced using different 
concentrations of Xantural® ranging between 0.1-0.5%w/v (recommended concentration 
range as suspending agent) and analysed at five different shear stresses at 20°C. The 
results (Figure 3) showed that Xantural® 180 displayed pseudoplastic properties which 
provide desirable flow properties with the largest change in apparent viscosity being 
observed for the highest concentration of Xantural® (0.5% v/v).  These studies were 
followed up by assessing the theoretical rate of sedimentation for ramipril in Xantural® using 
Stokes’ equation and experiments to confirm the rate and volume of sedimentation. 
Suspensions with the different concentrations of Xantural® were prepared and inspected at 
various time points over a four week period. The results showed (data not included) that 
there was no sedimentation observed at any of the time points for the entire range of 
concentrations investigated and the zeta potential was within +/-25mV range. Similarly, 
particles in a suspension can also give rise to ostwald ripening or crystal growth. Particle 
size is directly related to the rate of sedimentation, an increase in particle size via Ostwald 
ripening will lead to destabilisation of a stable suspension. Particle size measurements were 
performed after heating and cooling cycles to investigate Ostwald ripening. The findings from 
these studies (data not included) showed that there was no increase in particle size when 
subjected to temperature changes between 4 and 40OC. 
The final composition and process for preparing ramipril suspensions included production of   
0.1%w/v Xantural® 180 solution, into which 1mg/ml ramipril was then added slowly with 
vigorous stirring to ensure it is evenly distributed throughout the vehicle. This stage was 
followed by the addition of sodium meta bisulphate (10mg/ml; antioxidant), xylitol (400mg/ml; 
sweetener), sodium benzoate (5mg/ml; preservative) and strawberry flavour (0.2%v/v).   The 
pH of the final formulation was 4.25.  
 For all the optimised dosage forms, it was inevitable to include lowest possible 
concentration of preservatives as the primary vehicle is water and supports microbial growth. 
Taste assessment studies including indirect methods to evaluate taste such as drug release 
and dissolution testing (which are generally used for taste masked drug and require 
validation through direct taste assessment studies) have not been included as there are no 
taste related issues reported for ramipril. Indeed the inclusion of sweeteners and flavours in 
all the different dosage forms as well the formulation of drug complexed cyclodextrin liquid 
will ensure patient acceptability and compliance without any concerns for palatability. 
Following formulation profiling together with investigation of optimal process and excipient 
parameters that meet the TPPP, the next stage of evaluation consisted of stability testing 
and subsequent drug absorption and genomic analysis.  
Stability Analysis 
 Over the course of six month for stability testing at accelerated conditions at 40°C 
and 75% relative humidity, the drug content of the formulations fell below 95% of the starting 
dose indicating that the formulations failed to display adequate stability in accordance with 
ICH guidelines. pH remained constant for the duration of the stability testing in accelerated 
conditions. At long term conditions at 25°C and 60% relative humidity, drug content for all of 
the formulations remained >95% of the starting dose and pH remained constant for the 
duration of the 12 month testing period. Additionally, all formulations maintained their 
aesthetics. Suspension formulations did not display any sedimentation throughout the study 
suggesting that the inherent limitations of physical instability experienced by many 
suspension based formulations was successfully overcome and that sedimentation was 
totally prevented.  
 Degradation seen under accelerated conditions is possibly as a result of the elevated 
temperature. Ramipril diketopiperazine (DKP) degradate is the primary degradation 
compound for ramipril. Degradation occurs through intramolecular condensation with the 
formation of a second amide bond.(22) The pH of the formulation in both accelerated and 
long term conditions did not change beyond the acceptance levels for the formulation. 
Additionally, the appearance and odour of the formulations remained acceptable for the 
duration of the stability testing in both long term and accelerated conditions. The results 
show that formulations do not require refrigeration but would require storage in a cool 
location (<25°C).  
 
In Vitro and In Vivo Evaluation of Ramipril Formulations 
Assessment of Absorption In Vitro 
 Permeability coefficient or apparent permeability of a molecule (Papp) is considered a 
reliable indicator for the expected in vivo drug absorption (Fraction Absorbed (fa)). It is 
generally accepted that completely absorbed drugs have Papp >1x10-6cm/s (LogPapp > -6) 
and incompletely or poorly absorbed drugs have Papp <1x10-6cm/s (LogPapp < -6).(23)  
 Following permeability experiments, samples were analysed via HPLC and the 
findings from which were plotted to reveal the percentage of drug that was transported from 
the apical to the basolateral compartment of the transwell as a factor of time. TEER values 
were measured before and after the permeability experiments for each transwell to ensure 
the integrity of the monolayer. In all cases the TEER remained above an acceptable level of 
350Ω cm2.  
  Previous investigations into Papp reported permeability coefficients ranging from 
approximately 5x10-8 to 5x10-5cm/s. Permeability coefficients for ramipril formulations in the 
current investigations were in keeping with these findings and demonstrated  limited 
absorption of the drug for all the different formulations (Figure 5)(23).  
Genomic Assessment of Caco-2 Following In Vitro Absorption Assay 
 Investigation into gene expression changes of Caco-2 cells following drug transport 
studies were carried out to identify link between the predicted drug permeability and the 
expression of the genes which code for the intestinal transporter of  ramipril (SLC15A1 and 
SLC15A2).(5) The expression patterns for Caco-2 cells in their basal state were used as a 
control and compared to cells which had been exposed to ramipril formulations. 
 The genes from the solute carrier transporters (SLC) superfamily for which a 
significant change in gene expression was seen were used in KEGG pathway identification. 
For the ramipril solution produced using cyclodextrin as a solubiliser there was significant 
effect on 10 genes in the SLC family for which a >2 fold up regulation was observed. For the 
ramipril co solvent solution, there was significant effect on 26 genes in the SLC family. The 
ramipril suspension caused significant up regulation of 29 genes in the SLC family.   
 KEGG pathway analysis of the significantly up regulated SLC transporter genes 
returned pathway information for SLC16A10 which codes for TAT1. TAT1 is present in the 
basolateral membrane of intestinal epithelial cells and transports neutral amino acids into 
and out of the blood.(24,25) SLC16A10 was seen to be significantly up regulated for all of 
the ramipril formulations. There were significant expressional changes for numerous SLC 
transporters in the protein absorption pathway across the intestinal epithelial but not 
SLC15A1, the transporter for which ramipril is a substrate. SLC15A1 codes for the PEPT1 
transporter which is present in the apical membrane of intestinal epithelial cells and 
responsible for the absorption of small peptides.(26,27) The pathways and proteins, for 
which the SLC genes displayed significant modification in gene expression could be linked to 
ramipril absorption as TAT1 similar to PETP1 is involved in protein absorption pathways. 
The changes in expression levels could have resulted following interaction with the API in 
the formulations, however the excipients present could have also had an effect. This would 
account for up regulation in genes coding for transporter proteins which would not have 
necessarily been anticipated as a result of interaction with the API alone. This lends strength 
to the recently developing ideology that excipients potentially possess biological activity and 
are not inactive ingredients.(28,29) 
Assessment of Absorption In Vivo 
 The plasma concentration-time profile for the formulations for in vivo absorption is 
shown in Figure 5. From the plasma concentration-time profile, values for area under the 
curve (AUC), CMAX and TMAX were determined and are shown in Table 2. Ramipril AUC 
values were within the anticipated range as its bioavailability is known to be highly variable 
between individuals with reports showing variation ranging between 6-60%. (4) Ramipril 
showed a CMAX of 10.48 µg/mL for the solution produced using  co-solvent, 13.04µg/ml for 
the ramipril suspension and 29.58µg/mL for the ramipril solution produced using cyclodextrin 
as a solubiliser. 
 The findings for CMAX and TMAX reveal interesting findings; ramipril solution produced 
using co-solvent and the ramipril suspension showed TMAX at 2.5h after administration. 
However, ramipril solution produced using cyclodextrin showed a much earlier TMAX 
occurring only 0.75h following administration. As the only formulation component which is 
unique to the ramipril solution produced using cyclodextrins as a solubiliser is the HP-β-CD it 
is possible that this excipient is responsible for the earlier TMAX and higher CMAX. There is 
evidence that HP-β-CD decreases GI transit time in rats thus shortening the time taken for 
the drug to reach the site of absorption.(30) As ramipril is absorbed mainly in the Ileum, this 
would result in the formulation reaching the site of absorption more rapidly. Ordinarily, a 
decrease in intestinal residence time would see a decrease in absorption due to a shorter 
absorption window however cyclodextrins have the ability to improve drug absorption. It is 
generally recognized that cyclodextrins act as true carriers by keeping the hydrophobic drug 
molecules in solution and deliver them to the surface of the biological membrane. The 
relatively lipophilic membrane has low affinity for the hydrophilic cyclodextrin molecules and 
therefore they remain in the aqueous membrane exterior, e.g. the aqueous vehicle system or 
GI fluid. Conventional penetration enhancers, such as alcohols and fatty acids, disrupt the 
lipid layers of the biological barrier however, cyclodextrins, on the other hand, act as 
penetration enhancers by increasing drug availability at the surface of the biological barrier.  
Conclusions 
 Oral liquid ramipril formulations targeting the paediatric population were produced 
addressing the needs outlined in EMA/480197/2010. The current study has outlined for the 
first time the different oral liquid formulations of ramipril that can be produced without the 
need for inclusion of high concentration of excipients that are not recommended for use in 
paediatric formulations. The results provide the formulator with the option of developing 
either a solution or suspension based formulation which has a shelf life of twelve months. 
Biopharmaceutical evaluation of the formulated products has shown that they exhibit similar 
permeability as well as pharmacokinetic profile as reported in clinical literature.  Results from 
these investigations provide the platform to formulate better medicines for children using 
simple, cost effective and scalable processing parameters.   
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Figure   1   ‐  Phase   solubility   profile   for   Ramipril   complexed  with   HP‐β‐CD.   Six  
concentrations   of   cyclodextrin   were   produced   in   distilled   water   from   1.2mM   to  
3.75µM  using   serial  dilution.  To   these  excess  Ramipril  was  added. Solutions  were   left  
stirring  for  1  hour  before  samples  were  filtered  and  prepared  for  HPLC  analysis  (n=3). 
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 Figure   2   ‐  Effect   of  pH   on   Ramipril   solubility   in   the   presence  of   HP‐β‐CD.   Six  
concentrations   of   cyclodextrin   were   produced   in   distilled   water   from   1.2mM   to  
3.75µM  using  serial  dilution.  These  were  produced   in  solutions  of  pH  3,  5  and  7  and  to  
these   excess   Ramipril  was  added.   Solutions   were   left   stirring   for  1  hour  before  
samples  were  filtered  and  prepared for HPLC  analysis  (n=3). 
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 Figure   3   ‐  Suspension  viscosity   under   variable   shear   stress   in   Ramipril   suspensions.  
Ramipril   suspensions   (n=3)   in   concentrations   of   Xanatural   from   0.1‐0.5%w/v   were  
prepared   and   suspension   Rheology   was   investigated   to   provide   information   on   flow  
properties   by   measuring   suspension   viscosity   at   different   shear   rates  using   a 
Brookfield   DV   –   I   +   Viscometer  at   shear   rates   of   0.08,   0.16,   0.32,   0.83   and   1.67 
reciprocal   seconds..   As   expected   all   concentrations   of   Xanatural   180   displayed  
pseudoplastic   flow  with   the   viscosity   at   each  measurement   point  being  proportional  
to  the  concentration  of  Xanatural  180  present   in  the  solution.     
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 Figure   4   ‐  Apparent   permeability   values   for   Ramipril  formulations.   It   is   generally  
accepted   that  completely  absorbed  drugs  have  Papp  >1x10‐6cm/s.   (LogPapp  >   ‐6)  and 
incompletely   or   poorly   absorbed  drugs   have   Papp   <1x10‐6cm/s.  (LogPapp  <   ‐6). 
Permeability   coefficients   for   Ramipril   formulations   are   in   keeping  with   these   values, 
Ramipril   has   limited  absorption   and   this   is   supported   with   all   of   the   Ramipril  
formulations  displaying LogPapp  <  ‐6cm/s (n=3).   
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 Figure   5   ‐  Plasma   Concentrations   Following   Oral  Administration   (n=3).  Ramipril  
showed   a   CMAX   range   of   10.48   µg/mL   for   the   Ramipril   solution   produced   using   a   co‐
solvent,   13.04µg/ml   for   the   Ramipril   Suspension   and  29.58µg/mL   for   the  Ramipril  
solution  produced  using  cyclodextrin  as  a  solubiliser.  Ramipril  solution  produced  using 
a  co‐solvent  and  the  Ramipril  suspension  of  TMAX  2.5h.  The  Ramipril  solution  produced  
using   cyclodextrin   however   shows   a  much   earlier   TMAX   occurring  only   0.75h   following  
administration. 
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Table 1 - Summary of Ramipril Formulation Compositions 
Ramipril Cyclodextrin Solution  Ramipril Co‐solvent Solution  Ramipril Suspension 
Ramipril (1mg/ml)  Ramipril (1mg/ml)  Ramipril (1mg/ml) 
HP‐β‐CD (3.51mg/ml)  Acetic Acid (0.02% v/v)  Xanatural 180 (1mg/ml) 
Ascorbic Acid (0.1mg/ml)  Ascorbic Acid (0.1mg/ml)  Sodium Metabisulphate (10mg/ml) 
Propyl Paraben (0.1mg/ml)  Propyl Paraben (0.1mg/ml)  Sodium Benzoate (5mg/ml) 
Butyl Paraben (0.06mg/ml)  Butyl Paraben (0.06mg/ml)  Xylitol (400mg/ml) 
Xylitol (200mg/ml)  Xylitol (200mg/ml)  Strawberry Flavour (0.2% v/v) 
Orange Flavour (0.1% v/v)  Orange Flavour (0.1% v/v) 
 
   
Table 2 – In Vivo - AUC, CMAX and TMAX results for absorption of Ramipril following oral administration of Ramipril 
oral liquid formulations.  
Formulation  AUC (ug*h/mL)  CMAX (ug/ml)  TMAX (h) 
Ramipril Cyclodextrin Solution  15.07  29.58  0.75 
Ramipril Co‐solvent Solution  7.94  10.48  2.5 
Ramipril Suspension  18.54  3.84  2.5 
 
 
